Pharmaceutical News

RSS

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

27 Feb 2016

New drug shows promise against Huntington's disease

A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

27 Feb 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.

26 Feb 2016

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Eli Lilly and Company announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for ixekizumab for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union who are candidates for systemic therapy.

26 Feb 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

Nearly two-thirds of herbal medicines have potential health risks to cancer patients

Nearly two-thirds of the herbal medicines used by cancer patients in the Middle East have potential health risks, according to a new survey led by Assistant Professor Eran Ben-Arye, of the Technion-Israel Institute of Technology.

26 Feb 2016

Researchers unravel biochemical action of antimalarial drug

Malaria is a worldwide menace. According to the Centers for Disease Control and Prevention, over 500,000 individuals died from malaria in 2013 alone. While treatments for the disease exist, cures can also take a hefty physical toll.

26 Feb 2016

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

A study published online ahead of print in the journal Medical Care shows that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2 percent to 53 percent.

26 Feb 2016

New Notre Dame research may lead to a therapy for Niemann-Pick Type C disease

Niemann-Pick Type C (NPC) disease is a rare, fatal neurodegenerative disease for which there is currently no cure. NPC primarily strikes children before and during adolescence and affects one in every 150,000 children. The disease causes cholesterol and other lipids to build up in the body's cells, which results in symptoms such as delayed motor development, deterioration of memory and balance, and seizures.

26 Feb 2016

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan plc, a leading global pharmaceutical company, today announced that the Company has received approval from the U.S. Food and Drug Administration to market ACZONE (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Immune-suppressing drug can improve cognitive ability of patients with schizophrenia

A recent study of a handful of patients supports mounting evidence that targeted suppression of inflammation packaged with standard therapy can improve the cognitive ability of patients with schizophrenia, physician-scientists report.

25 Feb 2016

Ketamine appears to be safe, effective for difficult-to-sedate ER patients

For the small segment of the emergency population whose acute behavioral disturbance does not respond to traditional sedation, ketamine appears to be effective and safe, according to an Australian study published online last Thursday in Annals of Emergency Medicine ("Ketamine for Difficult to Sedate Severe Acute Behavioral Disturbance in the Emergency Department").

25 Feb 2016

Stop TB Partnership's new initiative to increase access to two new life-saving TB medicines

The Stop TB Partnership's Global Drug Facility (GDF) will announce a new initiative to increase access to bedaquiline and delamanid - the two new life-saving medicines recently approved for the treatment of multi-drug resistant tuberculosis (TB). The GDF will share how it is expanding existing and developing new public-private partnerships to expedite and maximize access to these two critical medicines.

25 Feb 2016

Pharmaceutical News

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

New drug shows promise against Huntington's disease

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Nearly two-thirds of herbal medicines have potential health risks to cancer patients

Researchers unravel biochemical action of antimalarial drug

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

New Notre Dame research may lead to a therapy for Niemann-Pick Type C disease

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Immune-suppressing drug can improve cognitive ability of patients with schizophrenia

Ketamine appears to be safe, effective for difficult-to-sedate ER patients

Stop TB Partnership's new initiative to increase access to two new life-saving TB medicines

Study: Magnesium therapy can alleviate muscular symptoms in patients with Motor Neurone Disease

Vertical Pharmaceuticals launches breakthrough prenatal vitamin supplement: OB Complete Gold

Omega-3 fatty acids can lower risk of breast cancer in postmenopausal obese women

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

UEA research paves way for new wave of drugs to kill superbugs

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News